Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJesús F. San MiguelSBSara BringhenMMMaría‐Victoria Mateos

Discussion

Loading...

Member takes

Overview

Pooled analysis reveals isa-vrd improves progression-free survival in elderly patients, suggesting treatment effectiveness across frailty levels.

Key Points

  • To analyze the efficacy and safety of isa-vrd in elderly patients with or without frailty criteria.
  • Pooled analysis of IMROZ and phase 1b studies involving 336 patients.
  • Subgroup analysis by age (≤75 yrs, >75 yrs) and frailty criteria.
  • Overall response rate and minimal residual disease negativity assessed.
  • Median progression-free survival not reached for overall population and subgroups.
  • Overall response rate of 93.0% for ≤75 years and 92.3% for >75 years.
  • Minimal residual disease negativity rates were similar across age groups.

Cite This Study

Miguel et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df3ehttps://doi.org/10.1182/blood-2025-2267
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).2024 · 6 citations
  2. 2Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).2024 · 3 citations
  3. 3Comparative analysis of subcutaneous Isa VRd (ISASOCUT) and intravenous Isa VRd (IMROZ) in transplant-ineligible newly diagnosed multiple myeloma across age groups.2026
  4. 4Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)2025 · 1 citations
  5. 5Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)2025